The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zongertinib (Hernexeos) for adults with unresectable or metastatic non-squamous non–small cell lung cancer (NSCLC) harboring HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations as detected by an FDA-authorized test. Approval was based on clinical trial data demonstrating a 76% objective response rate in previously untreated patients, representing a meaningful improvement over standard-of-care therapy. The application was reviewed under the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program, with a final decision issued just 44 days after submission.
Drug Profile & Mechanism – zongertinib (Hernexeos)
- Profile: Oral, next-generation tyrosine kinase inhibitor designed to selectively target HER2 (ERBB2) activating mutations in NSCLC
- Mechanism: Inhibits the tyrosine kinase activity of mutant HER2 receptors, blocking downstream signaling pathways involved in tumor proliferation and survival, including MAPK and PI3K/AKT signaling cascades
- Target Population: Adults with unresectable or metastatic NSCLC harboring HER2 (ERBB2) TKD activating mutations detected by an FDA-approved companion diagnostic test
- Delivery System: Oral
- Treatment Schedule: Administered orally once daily until disease progression or unacceptable toxicity
Beamion LUNG-1 Study Design (NCT04886804)
- Study Design: Ongoing phase 1/1b, multicenter, open-label clinical trial evaluating zongertinib in patients with advanced HER2-mutant solid tumors, including NSCLC
- Study Objective: To evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of zongertinib in patients with HER2-mutant advanced solid tumors
- Participants: Adults with unresectable or metastatic HER2-mutant NSCLC, including both previously treated and treatment-naïve patients.
- Primary Endpoint: Objective response rate (ORR) as assessed by RECIST criteria
- Secondary Endpoints: Duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety.
Study Outcomes
- Primary Endpoint:
- Zongertinib demonstrated a 76% objective response rate in previously untreated HER2-mutant NSCLC, significantly exceeding historical response rates of approximately 30–45% with standard-of-care therapy
- Key Secondary Endpoints:
- Responding patients demonstrated durable tumor shrinkage, with sustained responses observed in a substantial proportion of participants during follow-up.
Regulatory Milestones
- Approval Date: February 26, 2026
- Regulatory Pathway: Accelerated Approval with Priority Review under the FDA Commissioner’s National Priority Voucher (CNPV) pilot program.
- Approval Review: The application was submitted on January 13, 2026 and approved within 44 days through the CNPV program, which provides enhanced communication and rolling review to expedite therapies addressing critical national health priorities.
Safety
- Overall Adverse Effects (AEs):
- The most common adverse reactions included diarrhea, rash, hepatotoxicity, fatigue, nausea, musculoskeletal pain, and upper respiratory tract infection.
- Severity of Toxicity:
- Serious adverse events associated with zongertinib include hepatotoxicity, left ventricular dysfunction, interstitial lung disease/pneumonitis, and embryofetal toxicity.
- Treatment Modifications:
- Dose interruption, reduction, or discontinuation may be required for patients experiencing significant treatment-related toxicities.
While AEs are common, the safety profile is manageable with proactive monitoring and adherence to guidelines, allowing patients to derive significant efficacy benefits from this chemotherapy-sparing, targeted therapy.
Development Status
- Current Status: FDA accelerated approval granted for adults with treatment-naïve or previously treated HER2-mutant unresectable or metastatic non-squamous NSCLC.
- Prescribing information: Available at Drugs@FDA
- Side Effect Reporting: Healthcare professionals are encouraged to report negative side effects of prescription drugs to the FDA MedWatch program.
Sources:
National Library of Medicine (U.S.). (n.d.). A study of zongertinib in participants with advanced solid tumors (Beamion LUNG-1) (NCT04886804). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04886804
U.S. Food and Drug Administration. (2026, February 26). FDA grants second approval under the national priority voucher pilot program. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-second-approval-under-national-priority-voucher-pilot-program
